[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 36 of about 36
1. Hirayama T, Matsumoto K, Kurosaka S, Muramoto M, Irie A, Iwamura M, Baba S, Uchida T, Ichinohe M, Iwabuchi K: [A case report: small cell carcinoma transformed from transitional cell carcinoma of the urinary bladder]. Hinyokika Kiyo; 2006 Aug;52(8):633-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case report: small cell carcinoma transformed from transitional cell carcinoma of the urinary bladder].
  • Cystoscopy showed a non-papillary tumor at the right side of the posterior wall.
  • Transurethral resection of the bladder tumor (TURBT) was performed.
  • Pathologic findings demonstrated superficial transitional cell carcinoma (TCC).
  • After two courses of neoadjuvant chemotherapy (MVAC), we performed radical cystectomy with Hautmann's continent reservoir.
  • Pathologic findings revealed small cell carcinoma without any TCC features.
  • We report a case of primary small cell carcinoma transformed from TCC of the urinary bladder.
  • [MeSH-major] Carcinoma, Small Cell / pathology. Carcinoma, Transitional Cell / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Aged. Cell Transformation, Neoplastic. Humans. Male. Neoplasm Recurrence, Local

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16972627.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


2. Dangle PP, Wang WP, Mayerson J, Mortazavi A, Monk P: Low grade papillary transitional cell carcinoma pelvic recurrence masquerading as high grade invasive carcinoma, ten years after radical cystectomy. World J Surg Oncol; 2008;6:103
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low grade papillary transitional cell carcinoma pelvic recurrence masquerading as high grade invasive carcinoma, ten years after radical cystectomy.
  • BACKGROUND: Tumor recurrence following radical cystectomy for a low-grade superficial transitional cell carcinoma (TCC) is exceedingly uncommon and has not been reported previously.
  • The pathology was consistent with a low-grade urothelial carcinoma.
  • After an unsuccessful treatment with cisplatin-based chemotherapy, the patient underwent a curative intent hemipelvectomy with complete excision of tumor and is disease free at one year follow-up.
  • CONCLUSION: A literature review related to this unusual presentation is reported and a surgical solutions over chemotherapy and radiotherapy is proposed.
  • [MeSH-major] Carcinoma, Papillary / pathology. Carcinoma, Transitional Cell / pathology. Neoplasm Recurrence, Local / surgery. Pelvic Neoplasms / surgery. Urinary Bladder Neoplasms / pathology

  • Genetic Alliance. consumer health - TEN.
  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2001 Apr;165(4):1124-8; discussion 1128-30 [11257652.001]
  • [Cites] J Clin Oncol. 2001 May 15;19(10):2638-46 [11352955.001]
  • [Cites] Urol Int. 2001;67(1):117-8 [11464136.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2781-9 [15199091.001]
  • [Cites] Hinyokika Kiyo. 1989 Jun;35(6):1055-9 [2801393.001]
  • [Cites] J Urol. 1994 Jan;151(1):31-5; discussion 35-6 [8254828.001]
  • [Cites] J Urol. 1995 Mar;153(3 Pt 2):1047-8 [7853557.001]
  • [Cites] Urol Int. 1998;61(2):126-7 [9873256.001]
  • [Cites] Yonsei Med J. 2005 Feb 28;46(1):181-3 [15744826.001]
  • [Cites] Jpn J Ophthalmol. 2006 Sep-Oct;50(5):469-73 [17013702.001]
  • [Cites] Hinyokika Kiyo. 2007 Mar;53(3):179-82 [17447488.001]
  • [Cites] J Urol. 2007 Dec;178(6):2308-12; discussion 2313 [17936804.001]
  • [Cites] Urology. 2009 Jan;73(1):210.e3-5 [18372021.001]
  • (PMID = 18826578.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2566572
  •  go-up   go-down


3. Baselli EC, Greenberg RE: Intravesical therapy for superficial bladder cancer. Oncology (Williston Park); 2000 May;14(5):719-29; discussion 729-31, 734, 737
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intravesical therapy for superficial bladder cancer.
  • Approximately 54,400 new cases of transitional cell carcinoma of the bladder were reported in the United States in 1999, with an estimated 12,500 deaths attributable to this cancer.
  • Close to 75% of all bladder tumors are confined to the urothelium (stage Ta, or carcinoma in situ), and nearly 30% of papillary tumors invade the lamina propria (stage T1).
  • Transurethral resection is the standard initial treatment for transitional cell carcinoma.
  • Intravesical therapy is an important adjunct to transurethral resection in patients with superficial bladder cancer, many of whom are at risk for disease recurrence and progression.
  • Cytotoxic and immunomodulating agents and, more recently, photosensitizers have demonstrated utility against superficial transitional cell carcinoma.
  • Recently, valrubicin (Valstar) won Food and Drug Administration (FDA) approval only for the treatment of refractory carcinoma in situ.
  • However, bacillus Calmette-Guérin (BCG) and mitomycin (Mutamycin) remain the most commonly used, most effective agents available for prophylaxis against recurrence and subsequent progression of superficial bladder cancer.
  • This article reviews traditional and alternative intravesical agents useful in the therapy and prophylaxis of superficial transitional cell carcinoma of the bladder.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. Antibiotics, Antineoplastic / therapeutic use. Antineoplastic Agents / therapeutic use. Carcinoma, Transitional Cell / drug therapy. Doxorubicin / analogs & derivatives. Photosensitizing Agents / therapeutic use. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Administration, Intravesical. Anticarcinogenic Agents / therapeutic use. Epirubicin / therapeutic use. Humans. Interferons / therapeutic use. Mitomycin / therapeutic use. Mycobacterium bovis. Neoplasm, Residual / drug therapy. Photochemotherapy. Thiotepa / therapeutic use

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. THIO-TEPA .
  • Hazardous Substances Data Bank. VALRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10853462.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Antibiotics, Antineoplastic; 0 / Anticarcinogenic Agents; 0 / Antineoplastic Agents; 0 / Photosensitizing Agents; 2C6NUM6878 / valrubicin; 3Z8479ZZ5X / Epirubicin; 50SG953SK6 / Mitomycin; 80168379AG / Doxorubicin; 9008-11-1 / Interferons; 905Z5W3GKH / Thiotepa
  • [Number-of-references] 32
  •  go-up   go-down


Advertisement
4. Kong CH, Singam P, Hong GE, Cheok LB, Azrif M, Tamil AM, Zainuddin ZM: Clinicopathological features of bladder tumours in a single institution in Malaysia. Asian Pac J Cancer Prev; 2010;11(1):149-52
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological features of bladder tumours in a single institution in Malaysia.
  • OBJECTIVE: To determine the clinicopathological features of bladder tumours encountered over a five year period in Universiti Kebangsaan Malaysia Medical Centre.
  • METHODS: Medical records of bladder tumour cases from 2005 till 2009 were retrospectively reviewed and tabulated.
  • The main histopathology was transitional cell carcinoma (TCC) (90.4%), followed by adenocarcinoma (6%), squamous cell carcinoma (1.2%), leiomyoma (1.2%) and myeloid sarcoma (1.2%).
  • Of the total, 5.3% were papillary urothelial tumours of low malignant potential, 33.3% pTa, 20% pT1, 10.7% pT2, 12.0% pT3 and 18.7% pT4.
  • There were ten radical cystectomies performed for transitional cell carcinomas; two had neobladder reconstruction whereas the other eight had ileal conduits.
  • All the adenocarcinomas and squamous cell carcinomas were treated by radiotherapy due to the advanced stage of the disease while the myeloid sarcoma received chemotherapy.
  • CONCLUSION: The incidence of bladder tumours is highest among the Chinese.
  • [MeSH-major] Adenocarcinoma / secondary. Carcinoma, Squamous Cell / secondary. Carcinoma, Transitional Cell / secondary. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Lymphatic Metastasis. Malaysia. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20593947.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


5. Andius P, Holmäng S: Bacillus Calmette-Guérin therapy in stage Ta/T1 bladder cancer: prognostic factors for time to recurrence and progression. BJU Int; 2004 May;93(7):980-4
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bacillus Calmette-Guérin therapy in stage Ta/T1 bladder cancer: prognostic factors for time to recurrence and progression.
  • OBJECTIVE: To report prognostic factors for time to recurrence and progression after bacillus Calmette-Guérin (BCG) prophylaxis in patients with stage Ta/T1 papillary bladder cancer.
  • PATIENTS AND METHODS: The clinical records were assessed retrospectively for 236 patients with papillary stage Ta/T1 bladder cancer treated with BCG between 1986 and 2000.
  • The effect of 13 variables on the time to recurrence and progression was evaluated using multivariate Cox proportional hazard regression and Kaplan-Meier analyses.
  • Patients with a negative first cystoscopy and maintenance BCG had a significantly longer time to recurrence than those treated with an induction course alone (P < 0.001).
  • The result of the first cystoscopy (P < 0.001), tumour grade (P = 0.003) and six or fewer initial instillations (P = 0.002) had prognostic importance for the time to progression.
  • Twenty-eight patients (12%) had a history of an upper tract tumour, which was 3-10 times the expected rate.
  • Age, number of tumours, number of positive cystoscopies, length of tumour history before BCG, BCG strain and treatment year had no influence on time to recurrence and progression.
  • CONCLUSIONS: Maintenance treatment does not seem to be necessary among patients with TaG1-G2 disease after a negative first cystoscopy, as the progression rate was very low.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. BCG Vaccine / therapeutic use. Carcinoma, Transitional Cell / drug therapy. Neoplasm Recurrence, Local / prevention & control. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Administration, Intravesical. Adult. Aged. Aged, 80 and over. Cystectomy / methods. Disease Progression. Epidemiologic Methods. Female. Humans. Male. Middle Aged. Time Factors

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15142147.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / BCG Vaccine
  •  go-up   go-down


6. Kamat AM, Dinney CP, Gee JR, Grossman HB, Siefker-Radtke AO, Tamboli P, Detry MA, Robinson TL, Pisters LL: Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients. Cancer; 2007 Jul 1;110(1):62-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients.
  • BACKGROUND: Micropapillary bladder carcinoma is a rare variant of urothelial carcinoma.
  • METHODS: The authors reviewed the records of 100 consecutive patients with micropapillary bladder cancer who were evaluated at The University of Texas M. D.
  • The TNM stage of disease at the time of presentation was Ta in 5 patients, carcinoma in situ (CIS) in 4 patients, T1 in 35 patients, T2 in 26 patients, T3 in 7 patients, T4 in 6 patients; N+ in 9 patients, and M+ in 8 patients.
  • Bladder-sparing therapy with intravesical bacillus Calmette-Guerin therapy was attempted in 27 of 44 patients with nonmuscle-invasive disease; 67% (18 patients) developed disease progression (>or=cT2), including 22% who developed metastatic disease.
  • Of 55 patients undergoing radical cystectomy for surgically resectable disease (<or=cT4a), 23 received neoadjuvant chemotherapy and 32 were treated with initial cystectomy, with no significant difference noted in stage distribution between the 2 groups.
  • For the 23 patients treated with neoadjuvant chemotherapy, the median OS was 43.2 months with 32% of patients still alive at 5 years.
  • For the 32 patients treated with initial cystectomy, the median survival had not been reached at the time of last follow-up, with 71% still alive at 5 years.
  • CONCLUSIONS: Micropapillary bladder cancer is associated with a poor prognosis.
  • Intravesical therapy appears to be ineffective in this disease and patients with surgically resectable disease should be offered early radical cystectomy.
  • [MeSH-major] Carcinoma, Papillary / pathology. Carcinoma, Transitional Cell / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Cystectomy / methods. Female. Hospitals, University. Humans. Male. Middle Aged. Neoadjuvant Therapy / methods. Neoplasm Staging. Retrospective Studies. Survival Analysis. Texas

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 American Cancer Society.
  • (PMID = 17542024.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Bassi PF, Spinadin R, Carando R, Dal Moro F, Abatangelo G, Piazza N, Tavolini IM: [Mitoxantrone chemoprophylaxis for multirecurrent multifocal superficial bladder tumours: results of a phase 2 controlled study]. Arch Ital Urol Androl; 2003 Dec;75(4):202-4
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mitoxantrone chemoprophylaxis for multirecurrent multifocal superficial bladder tumours: results of a phase 2 controlled study].
  • [Transliterated title] Mitoxantrone chemoprophyaxis for multirecurrent multifocal superficial bladder tumours: results of a phase 2 controlled study.
  • Twenty-three patients with multifocal superficial bladder cancer (stage Ta - T1) unresponsive to at least 3 different intravesical agents, were enrolled in a phase II study in order to evaluate the prophylactic effects of intravesical Mitoxantrone (20 mg) after complete endoscopic resection (TUR) of any papillary tumor.
  • The progression rate is acceptable; the side effects are at least similar to those available in the literature, but in our experience, Mitoxantrone has no prophylactic effects against superficial bladder cancer unresponsive to previous treatment.

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15005494.001).
  • [ISSN] 1124-3562
  • [Journal-full-title] Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
  • [ISO-abbreviation] Arch Ital Urol Androl
  • [Language] ITA
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BZ114NVM5P / Mitoxantrone
  •  go-up   go-down


8. Ro JY, Shen SS, Lee HI, Hong EK, Lee YH, Cho NH, Jung SJ, Choi YJ, Ayala AG: Plasmacytoid transitional cell carcinoma of urinary bladder: a clinicopathologic study of 9 cases. Am J Surg Pathol; 2008 May;32(5):752-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasmacytoid transitional cell carcinoma of urinary bladder: a clinicopathologic study of 9 cases.
  • In this report, we summarized the clinicopathologic features of 9 cases of plasmacytoid transitional cell carcinoma (TCC) of the urinary bladder, a rare variant of TCC.
  • Cystoscopic findings revealed a dominant solid mass with surrounding multiple papillary lesions in 6 cases and multiple masslike lesions in 3 other cases.
  • Four patients were treated by radical cystectomy with chemotherapy, 2 by radical cystectomy alone, 1 each by chemotherapy or intravesical bacillus Calmette-Guerin infusion alone, and 1 did not receive any further therapy.
  • Eight of 9 cases were associated with high-grade TCC, and transitional cell carcinoma in situ was present in 4 cases.
  • Interestingly, plasmacytoid transitional cell carcinoma in situ was noted in 1 case.
  • [MeSH-major] Carcinoma, Transitional Cell / pathology. Plasma Cells / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Carcinoma in Situ / pathology. Cell Nucleus / pathology. Combined Modality Therapy. Cystoscopy. Cytoplasm / pathology. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18379419.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


9. Izawa JI, Slaton JW, Kedar D, Karashima T, Perrotte P, Czerniak B, Grossman HB, Dinney CP: Differential expression of progression-related genes in the evolution of superficial to invasive transitional cell carcinoma of the bladder. Oncol Rep; 2001 Jan-Feb;8(1):9-15
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of progression-related genes in the evolution of superficial to invasive transitional cell carcinoma of the bladder.
  • It is generally accepted that there are dichotomous biologic pathways that lead to the development of either: i) superficial papillary (Ta) transitional cell carcinoma (TCC) or ii) precursor lesions to muscle-invasive (CIS, T1) TCC and muscle-invasive (> or =T2) TCC.
  • Using a colorimetric in situ hybridization technique, we examined the expression of mRNAs of several progression-related genes in archival, pathologic specimens from 77 patients with bladder TCC.
  • Gene expression was normalized using poly (dT) and the expression of each factor in a panel of specimens of normal urothelium.
  • VEGF, bFGF, IL-8, and MMP-9 expression was increased in muscle-invasive compared with superficial papillary tumors, (p<0.05) and VEGF expression was increased in muscle-invasive tumors compared with CIS specimens (p<0. 05).
  • bFGF, IL-8, and EGFR expression was increased in CIS specimens compared with superficial papillary tumors (p<0.05).
  • The pattern of expression of bFGF, VEGF, IL-8, MMP-9, and EGFR represent the divergent developmental pathways in the pathogenesis of bladder TCC, which characterizes superficial or invasive bladder cancer. bFGF, IL-8, and EGFR appear to be upregulated in early precursor lesions (CIS), whereas VEGF appears to be upregulated at later stages in the development of muscle-invasive TCC.
  • [MeSH-major] Carcinoma, Transitional Cell / genetics. Gene Expression Regulation, Neoplastic. Neoplasm Proteins / genetics. Urinary Bladder Neoplasms / genetics
  • [MeSH-minor] Carcinoma in Situ / genetics. Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Colorimetry. Disease Progression. Endothelial Growth Factors / biosynthesis. Endothelial Growth Factors / genetics. Growth Substances / biosynthesis. Growth Substances / genetics. Humans. Image Processing, Computer-Assisted. In Situ Hybridization. Interleukin-8 / biosynthesis. Interleukin-8 / genetics. Lymphokines / biosynthesis. Lymphokines / genetics. Matrix Metalloproteinase 9 / biosynthesis. Matrix Metalloproteinase 9 / genetics. Neoplasm Invasiveness. Neoplasm Staging. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. RNA, Neoplasm / biosynthesis. RNA, Neoplasm / genetics. Receptors, Growth Factor / biosynthesis. Receptors, Growth Factor / genetics. Staining and Labeling. Vascular Endothelial Growth Factor A. Vascular Endothelial Growth Factors

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11115562.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-16672; United States / NCI NIH HHS / CA / CA56973; United States / NCI NIH HHS / CA / CA67914
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] GREECE
  • [Chemical-registry-number] 0 / Endothelial Growth Factors; 0 / Growth Substances; 0 / Interleukin-8; 0 / Lymphokines; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Receptors, Growth Factor; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factors; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


10. Mack D, Höltl W, Bassi P, Brausi M, Ferrari P, de Balincourt C, Sylvester R, European Organization for Research and Treatment of Cancer Genitourinary Group: The ablative effect of quarter dose bacillus Calmette-Guerin on a papillary marker lesion of the bladder. J Urol; 2001 Feb;165(2):401-3
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The ablative effect of quarter dose bacillus Calmette-Guerin on a papillary marker lesion of the bladder.
  • PURPOSE: Low dose bacillus Calmette-Guerin (BCG) for stage TaT1 transitional cell carcinoma of the bladder has been given in various studies with the aim of decreasing side effects while maintaining the same efficacy as full dose bacillus Calmette-Guerin.
  • We examined the ablative activity and incidence of side effects of intravesical quarter dose BCG given for a papillary marker lesion of the bladder.
  • MATERIALS AND METHODS: Included in our study were 44 patients with primary or recurrent, multiple but no more than 10 lesions of stage pTaT1, grades 1 to 2 transitional cell carcinoma of the bladder.
  • Intravesical treatment begun 14 days after the complete transurethral resection of all visible tumors except 1 marker lesion no larger than 1 cm. consisted of instillations of 30 mg.
  • CONCLUSIONS: Quarter dose BCG has a clear ablative effect on superficial bladder cancer with a 61% response rate.
  • [MeSH-major] Adjuvants, Immunologic / administration & dosage. BCG Vaccine / administration & dosage. Carcinoma, Transitional Cell / drug therapy. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Staging. Postoperative Care

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11176382.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 2U10 CA11488-25; United States / NCI NIH HHS / CA / 2U10 CA11488-28; United States / NCI NIH HHS / CA / 5U10 CA11488-26; United States / NCI NIH HHS / CA / 5U10 CA11488-27
  • [Publication-type] Clinical Trial; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / BCG Vaccine
  •  go-up   go-down


11. Berglund RK, Savage CJ, Vora KC, Kurta JM, Cronin AM: An analysis of the effect of statin use on the efficacy of bacillus calmette-guerin treatment for transitional cell carcinoma of the bladder. J Urol; 2008 Oct;180(4):1297-300; discussion 1300
MedlinePlus Health Information. consumer health - Statins.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An analysis of the effect of statin use on the efficacy of bacillus calmette-guerin treatment for transitional cell carcinoma of the bladder.
  • PURPOSE: Bacillus Calmette-Guerin is an effective immunotherapy for carcinoma in situ of the bladder and it reduces recurrence from resected papillary transitional cell carcinoma of the bladder.
  • Many patients receiving bacillus Calmette-Guerin therapy are concurrently taking statin agents, which have known immunomodulatory properties and may alter the performance of bacillus Calmette-Guerin.
  • Some data have suggested that patients taking a statin while on bacillus Calmette-Guerin therapy experience reduced clinical efficacy.
  • Time to recurrence and progression to surgery were compared between those taking and those not taking a statin by Kaplan-Meier methods and multivariable Cox regression controlling for stage and grade.
  • RESULTS: There were 245 (26%) patients taking a statin before bacillus Calmette-Guerin therapy and 707 not on statin therapy (74%).
  • Median time to recurrence was similar between those who did and those who did not use a statin.
  • On multivariable analysis statin use was not significantly associated with recurrence (hazard ratio 1.04; 95% CI 0.81, 1.34; p = 0.7) or progression to surgery (hazard ratio 0.77; 95% CI 0.52, 1.13; p = 0.17) after bacillus Calmette-Guerin therapy.
  • CONCLUSIONS: This retrospective study in a large cohort of patients showed no statistically significant association between statin use and recurrence or progression to open surgery in patients treated with bacillus Calmette-Guerin for transitional cell carcinoma of the bladder.
  • Based on these data patients should not be discouraged from taking statins while undergoing bacillus Calmette-Guerin treatment.
  • [MeSH-major] BCG Vaccine / therapeutic use. Carcinoma, Transitional Cell / drug therapy. Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use. Neoplasm Recurrence, Local / diagnosis. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Administration, Intravesical. Aged. Aged, 80 and over. Cohort Studies. Disease Progression. Drug Therapy, Combination. Evaluation Studies as Topic. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Prognosis. Proportional Hazards Models. Reference Values. Retrospective Studies. Risk Assessment. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18707737.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCG Vaccine; 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors
  •  go-up   go-down


12. Serretta V, Galuffo A, Pavone C, Allegro R, Pavone-MacAluso M: Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of bladder: Phase I-II study on marker lesions. Urology; 2005 Jan;65(1):65-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of bladder: Phase I-II study on marker lesions.
  • OBJECTIVES: To study the ablative activity of intravesical gemcitabine against superficial transitional cell carcinoma of the bladder at different doses and concentrations.
  • METHODS: A total of 27 patients were treated with intravesical gemcitabine after transurethral resection during which one to three papillary marker lesions were left unresected.
  • Bladder Tis was diagnosed in 2 patients with a CR at 3 and 8 months after treatment.
  • Systemic and local tolerability was excellent, and no treatment interruption was required.
  • CONCLUSIONS: Our experience has shown the good tolerability and potential efficacy of intravesical gemcitabine against recurrent transitional cell carcinoma of the bladder.
  • Gemcitabine might be proposed, if our results are confirmed by larger studies, as a second-line therapy in patients who cannot tolerate more aggressive intravesical therapy.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma, Transitional Cell / drug therapy. Deoxycytidine / analogs & derivatives. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Administration, Intravesical. Aged. Disease-Free Survival. Dose-Response Relationship, Drug. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Prodrugs / administration & dosage. Prodrugs / therapeutic use. Remission Induction. Salvage Therapy. Treatment Outcome

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Urology. 2005 Nov;66(5):1141-2; author reply 1142 [16286156.001]
  • (PMID = 15667865.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Prodrugs; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


13. Izawa JI, Grossman HB: Localized bladder cancer. Curr Treat Options Oncol; 2000 Dec;1(5):423-32
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localized bladder cancer.
  • Transitional cell carcinoma (TCC) of the bladder makes up 90% of bladder cancers.
  • Once the diagnosis of superficial TCC has been established, histologically based prognostic factors guide which therapy or combination of therapies is indicated in the management of individual patients.
  • Surgery alone (transurethral resection) is appropriate initial therapy for noninvasive papillary TCC.
  • For lamina propria invasive tumors and carcinoma in situ, intravesical immunotherapy with bacille Calmette-Guérin (BCG) is often the first line of treatment to decrease tumor recurrence and to possibly decrease progression and improve survival.
  • Intravesical chemotherapy and interferon are alternative therapies that can also decrease recurrence rates.
  • For BCG-refractory TCC, durable response rates with alternative intravesical therapies are low.
  • For superficial TCC that is refractory to endoscopic procedures and intravesical agents or for disease progression, radical cystectomy with neobladder formation or other forms of urinary diversion is the treatment of choice.
  • [MeSH-major] Carcinoma, Transitional Cell / therapy. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. BCG Vaccine / therapeutic use. Clinical Trials as Topic. Combined Modality Therapy. Cystectomy. Diet. Endoscopy. Humans. Immunotherapy. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / therapy. Survival Rate

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 1983 Dec;130(6):1083-6 [6644886.001]
  • [Cites] N Engl J Med. 1992 Mar 12;326(11):737-40 [1445507.001]
  • [Cites] Urol Clin North Am. 2000 Feb;27(1):137-46, [10696252.001]
  • [Cites] J Urol. 1999 Apr;161(4):1133-5; discussion 1135-6 [10081854.001]
  • [Cites] Urology. 2000 Feb;55(2):161-8 [10688071.001]
  • [Cites] Cancer Res. 1998 Aug 15;58(16):3603-10 [9721868.001]
  • [Cites] J Clin Oncol. 1995 Jun;13(6):1404-8 [7751885.001]
  • [Cites] Urol Clin North Am. 2000 Feb;27(1):103-13, ix [10696249.001]
  • [Cites] J Urol. 1995 Mar;153(3 Pt 2):934-41 [7853578.001]
  • [Cites] J Urol. 1996 Sep;156(3):962-6 [8709374.001]
  • [Cites] Urol Clin North Am. 2000 Feb;27(1):15-24, vii-viii [10696241.001]
  • [Cites] Urol Clin North Am. 2000 Feb;27(1):1-13, vii [10696240.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1298-301 [9552029.001]
  • [Cites] J Urol. 2000 Apr;163(4):1124-9 [10737480.001]
  • [Cites] J Clin Oncol. 1994 Jan;12 (1):7-13 [8270987.001]
  • [Cites] BJU Int. 2000 Mar;85(5):599-610 [10735935.001]
  • [Cites] Br J Urol. 1998 May;81(5):692-8 [9634043.001]
  • [Cites] Urol Clin North Am. 1992 Aug;19(3):455-65 [1636230.001]
  • [Cites] J Urol. 1998 Jun;159(6):1793-801 [9598463.001]
  • [Cites] J Urol. 1994 Jan;151(1):21-6 [8254816.001]
  • [Cites] Urol Clin North Am. 2000 Feb;27(1):171-8, xi [10696256.001]
  • [Cites] N Engl J Med. 1999 May 6;340(18):1390-7 [10228189.001]
  • [Cites] J Urol. 1999 Apr;161(4):1120-3 [10081851.001]
  • [Cites] CA Cancer J Clin. 2000 Jan-Feb;50(1):7-33 [10735013.001]
  • [Cites] J Natl Cancer Inst. 1993 Jul 21;85(14):1159-64 [8320745.001]
  • [Cites] J Urol. 1986 May;135(5):920-2 [3959241.001]
  • [Cites] Urology. 1997 Oct;50(4):529-35 [9338727.001]
  • [Cites] CA Cancer J Clin. 1998 Sep-Oct;48(5):269-84 [9742894.001]
  • [Cites] Semin Surg Oncol. 1997 Sep-Oct;13(5):291-8 [9259084.001]
  • [Cites] Urol Clin North Am. 2000 Feb;27(1):125-35, x [10696251.001]
  • [Cites] Eur Urol. 1995;28(4):284-90 [8575494.001]
  • [Cites] J Urol. 1999 Aug;162(2):445-50; discussion 450-1 [10411054.001]
  • [Cites] Cancer. 1999 Jun 25;87(3):118-28 [10385442.001]
  • (PMID = 12057150.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / BCG Vaccine
  • [Number-of-references] 34
  •  go-up   go-down


14. Thalmann GN, Markwalder R, Walter B, Studer UE: Long-term experience with bacillus Calmette-Guerin therapy of upper urinary tract transitional cell carcinoma in patients not eligible for surgery. J Urol; 2002 Oct;168(4 Pt 1):1381-5
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term experience with bacillus Calmette-Guerin therapy of upper urinary tract transitional cell carcinoma in patients not eligible for surgery.
  • PURPOSE: Carcinoma in situ and urothelial tumors of the upper urinary tract become problematic in cases of bilateral occurrence or solitary kidney.
  • Perfusions with bacillus Calmette-Guerin (BCG) have been reported beneficial, however, only long-term results will determine the validity of this treatment.
  • MATERIALS AND METHODS: We retrospectively evaluated the results of BCG therapy for upper urinary tract disease in 37 patients.
  • All 37 patients had undergone previous surgical treatment for urothelial cancer, had a positive cytology or biopsy for upper urinary tract cancer and were ineligible for radical nephroureterectomy with a bladder cuff.
  • After placement of a 10Fr nephrostomy tube with the patient under local anesthesia 6 weekly perfusions of BCG were administered after radiological documentation of unhindered flow from the renal pelvis to the bladder or urinary diversion.
  • A total of 25 renal units were treated with curative intent for carcinoma in situ and 16 renal units were treated for Ta or higher urothelial tumors in an adjuvant setting after endoscopic resection.
  • In 1 patient BCG inflammation and in 2 others severe septicemia developed after the first perfusion.
  • BCG perfusion therapy did not alter renal function.
  • Of the 37 patients 14 (38%) died of urothelial cancer, 11 of other causes (29%) and 12 (33%) are alive.
  • CONCLUSIONS: BCG perfusion therapy of the upper urinary tract for papillary tumors or carcinoma in situ is a valid treatment option with acceptable side effects for patients not amenable to conventional radical surgical therapy.
  • BCG therapy of upper urinary tract urothelial tumors may prevent patients from requiring dialysis and provides cure in those with carcinoma in situ of the upper urinary tract.
  • In this negatively selected patient population BCG buys time for some but does not provide cure except for carcinoma in situ.
  • [MeSH-major] BCG Vaccine / therapeutic use. Carcinoma in Situ / drug therapy. Carcinoma, Transitional Cell / drug therapy. Kidney Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Nephrectomy. Nephrostomy, Percutaneous. Perfusion. Retrospective Studies. Survival Rate. Ureter / pathology. Ureter / surgery. Ureteral Neoplasms / drug therapy. Ureteral Neoplasms / mortality. Ureteral Neoplasms / pathology. Ureteral Neoplasms / surgery. Urinary Bladder Neoplasms / drug therapy. Urinary Bladder Neoplasms / mortality. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / surgery. Urinary Diversion

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12352398.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCG Vaccine
  •  go-up   go-down


15. Amling CL: Diagnosis and management of superficial bladder cancer. Curr Probl Cancer; 2001 Jul-Aug;25(4):219-78
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and management of superficial bladder cancer.
  • Bladder cancer is the fourth leading cause of cancer in American men, accounting for more than 12,000 deaths annually.
  • Currently, cigarette smoking is by far the most common cause of bladder cancer, although occupational exposure to arylamines has been implicated in the past.
  • Initial radiologic evaluation usually includes the excretory urography (intravenous pyelography), although further evaluation of the renal parenchyma with ultrasound or computed tomography scanning has been advocated by some.
  • These radiologic studies are unable to provide adequate bladder imaging, and thus cystoscopy is required for the diagnosis of bladder cancer.
  • Most bladder cancers present as "superficial" disease, confined to the bladder mucosa or submucosal layer, without muscle invasion.
  • Superficial tumors consist of papillary tumors that are mucosally confined (Ta), papillary or sessile tumors extending into the lamina propria (T1), and carcinoma in situ, which occurs as "flat" mucosal dysplasia, which can be focal, diffuse, or associated with a papillary or sessile tumor.
  • It is important to identify those tumors at risk for recurrence or progression so that adjuvant intravesical therapies can be instituted.
  • Most are given intravesically on a weekly basis, although many studies suggest that a single instillation immediately after transurethral resection may be as good as a longer course of therapy.
  • Although all of these drugs have toxicity, they usually are well tolerated.
  • Intravesical bacille Calmette-Guérin (BCG) is an immunotherapeutic agent that when given intravesically is very effective in the treatment of superficial transitional cell carcinoma.
  • Compared with controls, BCG has a 43% advantage in preventing tumor recurrence, a significantly better rate than the 16% to 21% advantage of intravesical chemotherapy.
  • In addition, BCG is particularly effective in the treatment of carcinoma in situ, eradicating it in more than 80% of cases.
  • In contrast to intravesical chemotherapy, BCG has also been shown to decrease the risk of tumor progression.
  • Unfortunately, adverse effects associated with this prolonged therapy may limit its widespread applicability.
  • In those patients at high risk in whom BCG therapy fails, intravesical interferon-alpha with or without BCG may be beneficial in some.
  • Photodynamic therapy has also been used but is limited by its toxicity.
  • In patients who progress or do not respond to intravesical therapies, cystectomy should be considered.
  • With the development of orthotopic lower urinary tract reconstruction to the native urethra, the quality of life impact of radical cystectomy has been lessened.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Biomarkers, Tumor / analysis. Carcinoma, Transitional Cell / diagnosis. Carcinoma, Transitional Cell / therapy. Immunotherapy. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] ABO Blood-Group System. Administration, Intravesical. Adult. Aged. Diagnosis, Differential. Female. Hematuria / etiology. Humans. Incidence. Male. Middle Aged. Neoplasm Staging / methods. Photochemotherapy. Risk Factors. Surgical Procedures, Operative / methods. Urethra / surgery

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11514784.001).
  • [ISSN] 0147-0272
  • [Journal-full-title] Current problems in cancer
  • [ISO-abbreviation] Curr Probl Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABO Blood-Group System; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor
  • [Number-of-references] 179
  •  go-up   go-down


16. Manyak MJ, Ogan K: Photodynamic therapy for refractory superficial bladder cancer: long-term clinical outcomes of single treatment using intravesical diffusion medium. J Endourol; 2003 Oct;17(8):633-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy for refractory superficial bladder cancer: long-term clinical outcomes of single treatment using intravesical diffusion medium.
  • BACKGROUND: Diffuse superficial transitional-cell carcinoma (TCC) refractory to standard therapies poses a clinical dilemma.
  • Photodynamic therapy (PDT), which uses an interaction between absorbed light and a retained photosensitizing agent to destroy tissue, has been used to treat diffuse superficial bladder TCC, although there are few reports of long-term outcomes.
  • PATIENTS AND METHODS: A series of 34 patients, 29 with TCC carcinoma in situ (CIS) and 5 with multiple small papillary stage T(a) or T(1) lesions, received porfimer sodium (P) 48 hours before whole-bladder PDT with 630-nm laser light.
  • A 0.02% soybean emulsion diffusion medium was instilled into the bladder, and the laser optical fiber was positioned under triplanar sonography prior to PDT.
  • Four of the five patients with extensive papillary lesions did not respond.
  • The NR rate for patients with CIS with or without resected papillary lesions was 37%.
  • The mean time to recurrence in the CR group was 9.8 months, and five members of this group (36%) underwent cystectomy (mean time 20 months) for persistent/progressive disease (N = 3) or bladder contracture (N = 2).
  • In the NR group, 6 (43%) underwent cystectomy (mean time 14 months) for persistent/progressive disease.
  • Metastatic bladder cancer was the cause of death in only 4 of the 12 patients who have died.
  • Of the remaining 22 patients, 15 are still alive and have an intact bladder, nine with no disease and six with only superficial disease.
  • CONCLUSION: This is the first report of long-term results following whole-bladder PDT using diffusion medium for isotropic light distribution.
  • More than half of the patients with TCC refractory to traditional intravesical therapy received benefit from a single PDT session.
  • Patients with extensive flat papillary lesions do not appear to respond well.
  • Patients who achieve a CR have less likelihood of and longer time interval before needing cystectomy for progressive disease than NR patients.

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14622483.001).
  • [ISSN] 0892-7790
  • [Journal-full-title] Journal of endourology
  • [ISO-abbreviation] J. Endourol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 97067-70-4 / Dihematoporphyrin Ether
  •  go-up   go-down


17. Wang WM, Ye M, Chen JH, Zhang L, Kong L, Zhu YJ: [Comparison of endoscopic irsection and vaporization for superficial bladder cancer]. Zhonghua Zhong Liu Za Zhi; 2003 May;25(3):292-4
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparison of endoscopic irsection and vaporization for superficial bladder cancer].
  • OBJECTIVE: To evaluate the method and clinical value of endoscopic surgery by comparing endoscopic resection and vaporization for superficial bladder tumor.
  • METHODS: 396 patients with superficial bladder papillary transitional cell carcinoma were treated by endoscopic therapy.
  • 180 patients (Group A) were treated by transurethral resection of bladder tumor (TURBT) and 216 (Group B) by transurethral vaporization of bladder tumor (TVBT).
  • Periodic postoperative intra-vascular instillation of chemotherapy was given to both groups.
  • Operating time, amount of bleeding during operation, complications and recurrence rate were compared.
  • The operating time, recurrence rate in group B were similar to those in group A.
  • CONCLUSION: Transurethral vaporization of bladder cancer, with simplicity in maneuver, less bleeding and fewer complications, rates better in effectiveness and clinical value than resection.
  • [MeSH-major] Cystoscopy / methods. Electrosurgery / methods. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Time Factors

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12839699.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


18. Masuda A, Minakmi S, Usui Y, Arihara K, Nagata Y, Kawamura N: Advanced bladder cancer in a young female: a case report. Tokai J Exp Clin Med; 2001 Jul;26(2):39-43
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced bladder cancer in a young female: a case report.
  • We present a rare case of advanced bladder cancer in a young female.
  • A clinical examination revealed a papillary, broad-based bladder tumor with a clinical stage of T3, N3, M0.
  • Preoperatively, 3 courses of neoadjuvant chemotherapy with methotrexate, adriamycin, and cisplatin were performed, and proved to be effective.
  • Radical cystectomy was done and the histopathologically it was diagnosis as Grade 2 transitional cell carcinoma, which did not show any p53 gene mutation.
  • Bladder carcinoma in patients under 30 years of age tends to have a early stage and a low grade.
  • However, the above described 27-year-old female patient demonstrated the advanced stage bladder tumor.
  • Therefore, it should be kept in mind to accurately evaluate young patients with transitional cell carcinoma of the bladder and not to rule out the possibility of advanced disease even though a patient is young.
  • [MeSH-major] Carcinoma, Transitional Cell / diagnosis. Carcinoma, Transitional Cell / therapy. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] Adult. Age Factors. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Cystectomy. Doxorubicin / administration & dosage. Female. Humans. Methotrexate / administration & dosage. Neoadjuvant Therapy. Neoplasm Staging. Treatment Outcome

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11806441.001).
  • [ISSN] 0385-0005
  • [Journal-full-title] The Tokai journal of experimental and clinical medicine
  • [ISO-abbreviation] Tokai J. Exp. Clin. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


19. Dalbagni G: The management of superficial bladder cancer. Nat Clin Pract Urol; 2007 May;4(5):254-60
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The management of superficial bladder cancer.
  • From review of the currently available trial evidence, several clinical recommendations for bladder tumor management become apparent.
  • Transurethral resection should be done, but this procedure is prone to both overestimating and underestimating staging.
  • Data support the immediate postoperative instillation of a chemotherapeutic agent for patients with solitary, low-grade papillary tumors, whereas patients with multiple lesions might benefit from a more intensive adjuvant regimen.
  • Although the use of intravesical immunotherapy for reducing tumor progression or as maintenance therapy is controversial, bacillus Calmette-Guérin has demonstrated significant benefit for tumor prophylaxis when no obvious residual disease is present.
  • In this Review I present an overview of the management of nonmuscle invasive bladder cancer.
  • The most common intravesical chemotherapeutic agents are described as well as the impact of chemotherapy on the recurrence and progression of tumors.
  • The effect of intravesical immunotherapy in bladder cancer is explored as well as the role of early cystectomy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Transitional Cell / therapy. Cystectomy / methods. Immunotherapy / methods. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] Administration, Intravesical. BCG Vaccine / administration & dosage. Cystoscopy / methods. Female. Humans. Male. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / mortality. Neoplasm Staging. Prognosis. Randomized Controlled Trials as Topic. Risk Assessment. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17483810.001).
  • [ISSN] 1743-4289
  • [Journal-full-title] Nature clinical practice. Urology
  • [ISO-abbreviation] Nat Clin Pract Urol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCG Vaccine
  • [Number-of-references] 62
  •  go-up   go-down


20. Waidelich R, Stepp H, Baumgartner R, Weninger E, Hofstetter A, Kriegmair M: Clinical experience with 5-aminolevulinic acid and photodynamic therapy for refractory superficial bladder cancer. J Urol; 2001 Jun;165(6 Pt 1):1904-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical experience with 5-aminolevulinic acid and photodynamic therapy for refractory superficial bladder cancer.
  • PURPOSE: We determined whether photodynamic therapy after the oral administration of 5-aminolevulinic acid in patients with superficial bladder cancer that cannot be controlled by transurethral resection and intravesical bacillus Calmette-Guerin (BCG) immunotherapy would preserve the bladder, while stopping tumor progression.
  • Side effects of treatment were also assessed.
  • MATERIALS AND METHODS: We performed photodynamic therapy after the oral administration of 5-aminolevulinic acid in 24 patients with rapidly recurring, multifocal, BCG refractory superficial pTa-pT1 transitional cell carcinoma of the bladder and carcinoma in situ.
  • RESULTS: At a median followup of 36 months (range 12 to 51) 3 of the 5 patients with carcinoma in situ and 4 of the 19 with papillary tumors were free of recurrence.
  • Three patients were rendered disease-free by repeat photodynamic therapy with 5-aminolevulinic acid and 3 underwent cystectomy.
  • No phototoxic skin reaction or decreased bladder capacity was observed.
  • CONCLUSIONS: These initial clinical results suggest that photodynamic therapy with orally administered 5-aminolevulinic acid is effective as an organ preserving procedure for treating superficial bladder cancer even in patients with bacillus Calmette-Guerin refractory carcinoma.
  • [MeSH-major] Aminolevulinic Acid / therapeutic use. Carcinoma, Transitional Cell / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11371878.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


21. Saika T, Tsushima T, Nasu Y, Arata R, Kaku H, Kusaka N, Kumon H: Clinical study of G3 superficial bladder cancer without concomitant CIS treated with conservative therapy. Jpn J Clin Oncol; 2002 Nov;32(11):461-5
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical study of G3 superficial bladder cancer without concomitant CIS treated with conservative therapy.
  • OBJECTIVE: The treatment for superficial G3 transitional cell carcinoma (TCC) of the urinary bladder remains controversial.
  • It is important to reveal the clinical features of superficial G3 bladder cancer that can be treated conservatively.
  • PATIENTS AND METHODS: A total of 39 patients with primary superficial bladder cancer (Ta, T1) with G3 components but without concomitant carcinoma in situ (CIS), who had been treated initially with transurethral resection (TUR), were retrospectively analyzed for factors related to tumor recurrence, progression and survival.
  • Initial treatments were TUR alone in 18 patients and TUR with adjuvant therapy (intravesical chemotherapy or BCG therapy) in 21.
  • Factors examined included age, gender, morphology, size and number of tumors and adjuvant therapies.
  • The 5-year progression-free rate (75%) and survival rate (83%) in 39 patients with G3 did not show a statistically significant difference from those of the 109 patients with G1 or the 187 patients with G2 superficial bladder cancer who were treated with TUR initially.
  • Adjuvant therapies reduced the recurrence rate of the patients with G3.
  • Only tumor morphology, papillary or non-papillary, affected both the progression-free rate and the survival rate of patients with G3.
  • CONCLUSION: The results suggest that superficial G3 bladder cancer could be treated with TUR initially, especially for papillary tumors.
  • [MeSH-major] Carcinoma in Situ / surgery. Carcinoma, Transitional Cell / surgery. Cystectomy. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Prognosis. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12499418.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


22. Regalado JJ: Mixed micropapillary and trophoblastic carcinoma of bladder: report of a first case with new immunohistochemical evidence of urothelial origin. Hum Pathol; 2004 Mar;35(3):382-4
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed micropapillary and trophoblastic carcinoma of bladder: report of a first case with new immunohistochemical evidence of urothelial origin.
  • The micropapillary variant of urothelial carcinoma has a reported incidence of 0.7%.
  • Trophoblastic urinary carcinoma is very rare, with roughly 30 cases reported during the last century.
  • This is the first report of mixed micropapillary and trophoblastic bladder carcinoma.
  • His tumor contained choriocarcinomatoid areas with syncytiotrophoblasts, classic micropapillary carcinoma, conventional high-grade urothelial carcinoma, and flat carcinoma in situ.
  • Despite postoperative combination chemotherapy, he developed pulmonary and retroperitoneal metastases and died 20 months after presentation.
  • Because high-molecular-weight cytokeratin is expressed by urothelium but is rarely found in placental trophoblast or germ-cell choriocarcinoma, its presence in trophoblastic bladder carcinoma is new evidence that the latter is a transformed neoplasm of urothelial origin.
  • [MeSH-major] Carcinoma, Papillary / pathology. Carcinoma, Transitional Cell / pathology. Mixed Tumor, Malignant / pathology. Trophoblasts / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chorionic Gonadotropin, beta Subunit, Human / analysis. Cisplatin / therapeutic use. Combined Modality Therapy. Doxorubicin / therapeutic use. Fatal Outcome. Humans. Lymph Nodes / pathology. Male. Methotrexate / therapeutic use. Middle Aged. Salvage Therapy. Urologic Surgical Procedures, Male. Urothelium / pathology. Vinblastine / therapeutic use

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15017598.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin, beta Subunit, Human; 5V9KLZ54CY / Vinblastine; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate; M-VAC protocol
  •  go-up   go-down


23. Startsev VY: The role of combined method in organ-sparing treatment of muscle-invasive bladder cancer recurrences. Arch Ital Urol Androl; 2002 Jun;74(2):54-6
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of combined method in organ-sparing treatment of muscle-invasive bladder cancer recurrences.
  • OBJECTIVE: To determine the local control and survival of patients with bladder cancer recurrences (BCR) treated by operative methods, external beam radiotherapy (EBRT) and adjuvant chemotherapy (ACT).
  • MATERIALS AND METHODS: We have treated 180 patients (114 men, median age 64.5 years, range 56-73) with documented transitional-cell non-metastasized BC recurrences: 90 T2N0M0 and 90 T3aN0M0.
  • All patients received different operations (transurethral resection and partial cystectomies) and definitive EBRT (total dose varied from 50 to 64 Gy with a mean of 60.5 Gy, 5 days a week).
  • In a second group of patients we performed 3 courses of 4-drug regimen ACT administered with EBRT.
  • ACT consisting of cisplatin and adriamycin i.a. and methotrexate and vinblastin i.v. (M-VAC) was administered on the fourth week after radiation therapy.
  • The complete response rates in patients with clinical stage T2 and T3a disease was 64.4 and 44.4%, respectively and it was slightly higher in patients with a non-papillary cancer than in those with a papillary one.
  • CONCLUSIONS: Four-drug ACT is feasible without major toxicity and offers a potentially curative and conservative treatment for patients with localized muscle-invasive BC (bladder cancer) recurrences.
  • Bladder conservation therapy may be offered to selected patients with BC recurrences as an alternative option to radical cystectomy, and its use should be limited to teams of uro-oncologists, experienced in multi-modalty treatment.

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12161935.001).
  • [ISSN] 1124-3562
  • [Journal-full-title] Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
  • [ISO-abbreviation] Arch Ital Urol Androl
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / BCG Vaccine; 5V9KLZ54CY / Vinblastine; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


24. El-Ghobashy S, El-Leithy TR, Roshdy MM, El-Ganzoury HM: Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term follow-up. J Egypt Natl Canc Inst; 2007 Jun;19(2):121-6
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term follow-up.
  • PURPOSE: We analyzed the impact of a single Mitomycin C instillation in patients with low risk superficial bladder cancer with short and long-term follow-up.
  • PATIENTS AND METHODS: This study was conducted on 63 patients with low risk superficial bladder transitional cell carcinoma (TCC), admitted to the Urology Department, Theodor Bilharz Research Institute (TBRI) during the period from January 2002 to August 2005.
  • All patients had a 2 cm. or less single, papillary, primary or recurrent tumor and were disease-free for more than 1 year.
  • Patients with muscular invasion, G III tumor or bladder carcinoma in situ on pathological examination were excluded from the study.
  • The tumor was completely resected before patients were divided randomly into 2 arms: first group who have received no further treatment (control group) and a second group with a single immediate instillation of 30 mg.
  • CONCLUSION: These data confirm the positive effect of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer.
  • Thus, this approach is an alternative to observation or classic long-term intravesical chemotherapy.
  • Our study also suggests that cell implantation as a mechanism of early recurrence can be controlled or minimized with a single mitomycin C instillation.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Carcinoma, Papillary / drug therapy. Carcinoma, Transitional Cell / drug therapy. Mitomycin / administration & dosage. Neoplasm Recurrence, Local / epidemiology. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Administration, Intravesical. Case-Control Studies. Follow-Up Studies. Humans. Middle Aged. Neoplasm Staging. Prospective Studies. Risk Factors. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19034342.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 50SG953SK6 / Mitomycin
  •  go-up   go-down


25. Ruoppolo M, Gozo M, Milesi R, Spina R, Fragapane G: [Urethral recurrence of invasive carcinoma following BCG treatment for bladder Ca in situ]. Urologia; 2010 Oct-Dec;77 Suppl 17:72-7
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Urethral recurrence of invasive carcinoma following BCG treatment for bladder Ca in situ].
  • CIS is a flat, high-grade, non-invasive microscopic urothelial carcinoma.
  • It is considered a precursor of invasive bladder cancer.
  • CIS is classified as primary, secondary or concurrent, when occurred as isolated CIS without cuncurrent papillary tumors, or detected during the follow-up of patients with a previous papillary tumor, or finally in the presence of bladder neoplasm.
  • BCG is widely established as the treatment of choice for CIS with a success rate of approximately 70%.
  • Direct and prolonged contact between the urothelium and BCG is a prerequisite for successful therapy.
  • CIS may be present only in the epithelial lining of the prostatic urethra or in the ducts, or in the worst case it may be found in the prostatic tissue stroma.
  • 83 patients, enrolled from 1/1996 to 12/2005 at our urological department with CIS: primary (focal and multifocal) in 25, secondary in 7 and cuncurrent in 51 (associated with T1bG3 cancer in 37 cases), and urethral CIS in 5 and conservatively treated by TUR and intravescical instillations of BCG, 4 developed afterwords only invasive cancer of the urethra in the absence of bladder involvement.
  • Among the 4 patients, 3 were treated by cystoprostatourethrectomy and Platinum-based chemotherapy, 1 refused surgical treatment.
  • We conclude that prostatic/urethral involvement during follow-up after successful intravesical treatment with BCG in CIS represents a high risk of developing invasive and incontrolled cancer.
  • [MeSH-major] BCG Vaccine / therapeutic use. Carcinoma in Situ / therapy. Carcinoma, Transitional Cell / secondary. Urethral Neoplasms / secondary. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Cystectomy / methods. Disease Progression. Female. Follow-Up Studies. Humans. Immunotherapy. Male. Neoplasm Invasiveness. Organoplatinum Compounds / administration & dosage. Prostatectomy / methods. Prostatic Neoplasms / secondary. Risk. Treatment Outcome. Urethra / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21308679.001).
  • [ISSN] 1724-6075
  • [Journal-full-title] Urologia
  • [ISO-abbreviation] Urologia
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCG Vaccine; 0 / Organoplatinum Compounds
  •  go-up   go-down


26. Lopez-Beltran A, Ordóñez JL, Otero AP, Blanca A, Sevillano V, Sanchez-Carbayo M, Muñoz E, Cheng L, Montironi R, de Alava E: Cyclin D3 gene amplification in bladder carcinoma in situ. Virchows Arch; 2010 Nov;457(5):555-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclin D3 gene amplification in bladder carcinoma in situ.
  • Carcinoma in situ (CIS) is a non-papillary high-grade, potentially aggressive, and unpredictable manifestation of bladder urothelial carcinoma.
  • A sequential cohort series of 28 primary (isolated) or secondary (concomitant) bladder CIS samples in which there was enough tissue material to assess Cyclin D3 gene status by fluorescent in situ hybridization was the study group.
  • Type of bladder CIS (primary vs. secondary) was unrelated to recurrence- or progression-free survival in the current series.
  • None of primary CIS cases recurred on follow-up; nine secondary CIS recurred and four of them progressed to invasive bladder carcinoma HG T1 (n = 1), T2b N0M0 (n = 1), T3b N1M0 (n = 1) and T4aN1M1 (n = 1).
  • [MeSH-major] Biomarkers, Tumor / genetics. Carcinoma in Situ / genetics. Carcinoma, Transitional Cell / genetics. Cyclin D3 / genetics. Gene Amplification. Gene Expression Regulation, Neoplastic. Urinary Bladder Neoplasms / genetics
  • [MeSH-minor] Aged. Aged, 80 and over. BCG Vaccine / therapeutic use. Blotting, Western. Disease-Free Survival. Female. Humans. In Situ Hybridization, Fluorescence. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / genetics. Neoplasm Recurrence, Local / mortality. Proportional Hazards Models. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Scand J Urol Nephrol Suppl. 2008 Sep;(218):95-109 [18815924.001]
  • [Cites] Am J Pathol. 2002 Oct;161(4):1119-25 [12368185.001]
  • [Cites] J Urol. 1999 Mar;161(3):792-8 [10022686.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):4040-8 [15173019.001]
  • [Cites] Scand J Urol Nephrol. 2004;38(4):285-90 [15669587.001]
  • [Cites] Cancer Res. 2002 Feb 1;62(3):809-18 [11830537.001]
  • [Cites] Anticancer Res. 2008 Sep-Oct;28(5B):2893-900 [19031931.001]
  • [Cites] Cancer Lett. 2007 Jun 8;250(2):292-9 [17126995.001]
  • [Cites] Eur Urol. 2004 May;45(5):606-12 [15082203.001]
  • [Cites] J Urol. 2001 May;165(5):1488-91 [11342902.001]
  • [Cites] Clin Cancer Res. 2005 Jan 1;11(1):242-8 [15671552.001]
  • [Cites] Urology. 2003 Jun;61(6):1140-5 [12809883.001]
  • [Cites] Eur Urol. 2004 Feb;45(2):142-6 [14733997.001]
  • [Cites] Eur Urol. 2004 May;45(5):593-9 [15082201.001]
  • [Cites] Urology. 2005 Dec;66(6 Suppl 1):90-107 [16399418.001]
  • [Cites] Int J Cancer. 2009 Nov 1;125(9):2095-103 [19637316.001]
  • [Cites] Eur Urol. 2010 Jan;57(1):12-20 [19762144.001]
  • [Cites] Urology. 2001 Jan;57(1):60-5 [11164145.001]
  • [Cites] J Pathol. 2006 May;209(1):106-13 [16482499.001]
  • [Cites] Scand J Urol Nephrol Suppl. 1994;157:147-51 [7939446.001]
  • [Cites] Eur Urol. 2005 Sep;48(3):363-71 [15994003.001]
  • [Cites] Eur Urol. 2007 Jan;51(1):152-60 [17011114.001]
  • [Cites] Int J Cancer. 1996 Jan 26;65(3):323-7 [8575852.001]
  • [Cites] Cancer. 1999 Jun 1;85(11):2469-74 [10357420.001]
  • [Cites] J Natl Compr Canc Netw. 2009 Jan;7(1):48-57 [19176205.001]
  • [Cites] Urol Oncol. 2009 May-Jun;27(3):258-62 [18440839.001]
  • [Cites] Eur Urol. 2006 Jul;50(1):76-82 [16413663.001]
  • (PMID = 20821231.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / BCG Vaccine; 0 / Biomarkers, Tumor; 0 / CCND3 protein, human; 0 / Cyclin D3
  •  go-up   go-down


27. Kurth KH, Bouffioux C, Sylvester R, van der Meijden AP, Oosterlinck W, Brausi M: Treatment of superficial bladder tumors: achievements and needs. The EORTC Genitourinary Group. Eur Urol; 2000;37 Suppl 3:1-9
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of superficial bladder tumors: achievements and needs. The EORTC Genitourinary Group.
  • OBJECTIVE: The therapeutic objectives in the initial treatment of superficial tumors are to remove completely the tumor, to assess the need for further therapy and to plan the follow-up.
  • METHODS/RESULTS: The EORTC Genitourinary Group assessed the percentage of patients with recurrence at 3 months (3RR) after complete resection of all visible lesions taking into account the institution, the number of tumors at presentation and the year of treatment.
  • The bladder's unique location renders its mucosa accessible to instillation of chemotherapeutic and immunotherapeutic agents.
  • Cytostatics can be instilled into the bladder hours after surgery without severe complications.
  • A single early instillation within 6 h after transurethral resection (TUR) in patients with a solitary bladder tumor category T(a)/T(1)G(1) to G(3) could reduce the recurrence rate per year by nearly 50%.
  • The superiority of any of the commonly used intravesical drugs has never been demonstrated; the time to initiate therapy is important for treatment outcome.
  • Optimal results can be achieved by initiating treatment early (within 24 h after TUR) and for a duration of 6 months, and maintenance (>6 months) for patients with a delayed first instillation (>7 days after TUR).
  • Bacillus Calmette-Guérin (BCG) immunotherapy has been confirmed to be highly effective in the reduction of tumor recurrence, the treatment of residual papillary transitional cell carcinoma and the treatment of carcinoma in situ (CIS).
  • The response rate in the treatment of the papillary disease averages 55%, and for CIS 73%.
  • A direct prospective randomized comparison of BCG with intravesical chemotherapy has found it to be significantly superior to thiotepa, to doxorubicin and to mitomycin C when only patients with intermediate and high risk for recurrence were treated.
  • Clinical trials showed no superiority of BCG immunotherapy to chemotherapy in preventing progression to > or =T(2).
  • Preventive regulatory measures directed to decrease tobacco smoking and some occupational exposures to aromatic amines may contribute to the reduction of bladder cancer.
  • Bladder cancer is a multistep process making this tumor a candidate for chemoprevention.
  • To date, retinoids are the best-studied chemopreventive agents achieving mixed clinical results in superficial bladder tumors.
  • The follow-up of patients with all types of superficial tumors must be lifelong; unfortunately cystoscopy cannot be replaced yet by the control of any markers present or not in the urine.
  • [MeSH-major] Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] Adjuvants, Immunologic / therapeutic use. BCG Vaccine / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Humans. Immunotherapy. Neoplasm Recurrence, Local / prevention & control. Neoplasm Staging. Urologic Surgical Procedures

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 S. Karger AG, Basel
  • (PMID = 10828681.001).
  • [ISSN] 0302-2838
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] SWITZERLAND
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / BCG Vaccine
  • [Number-of-references] 67
  •  go-up   go-down


28. Dovedi SJ, Davies BR: Emerging targeted therapies for bladder cancer: a disease waiting for a drug. Cancer Metastasis Rev; 2009 Dec;28(3-4):355-67
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Emerging targeted therapies for bladder cancer: a disease waiting for a drug.
  • Urothelial cell carcinoma is the fifth most common cancer and the costliest to treat.
  • The standard of care, intravesical chemo- and immunotherapy, while effective, is associated with a considerable side-effect profile and approximately 30% of patients either fail to respond to treatment or suffer recurrent disease within 5 years.
  • Muscle-invasive bladder cancer is life threatening, showing modest chemosensitivity, and usually requires radical cystectomy.
  • Although bladder cancer is fairly well-genetically characterized, clinical trials with molecularly targeted agents have, in comparison to other solid tumors such as lung, breast and prostate, been few in number and largely unsuccessful, with no new agents being registered in the last 20 years.
  • Hence, bladder cancer represents a considerable opportunity and challenge for molecularly targeted therapy.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Carcinoma, Transitional Cell / drug therapy. Drug Delivery Systems. Drugs, Investigational / therapeutic use. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Administration, Intravesical. Angiogenesis Inhibitors / therapeutic use. BCG Vaccine / administration & dosage. BCG Vaccine / therapeutic use. Carcinoma in Situ / drug therapy. Carcinoma in Situ / economics. Carcinoma in Situ / epidemiology. Carcinoma in Situ / immunology. Carcinoma in Situ / surgery. Carcinoma, Papillary / drug therapy. Carcinoma, Papillary / economics. Carcinoma, Papillary / epidemiology. Carcinoma, Papillary / immunology. Carcinoma, Papillary / surgery. Cell Cycle / drug effects. Clinical Trials as Topic. Combined Modality Therapy. Cyclooxygenase 2 Inhibitors / therapeutic use. Cystectomy. Disease Management. Genetic Therapy. Humans. Intercellular Signaling Peptides and Proteins. Neoplasm Invasiveness. Neoplasm Proteins / antagonists & inhibitors. Neoplasm Proteins / physiology. Neovascularization, Pathologic / drug therapy. Signal Transduction / drug effects. Tumor Suppressor Protein p53 / antagonists & inhibitors

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19997963.001).
  • [ISSN] 1573-7233
  • [Journal-full-title] Cancer metastasis reviews
  • [ISO-abbreviation] Cancer Metastasis Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / BCG Vaccine; 0 / Cyclooxygenase 2 Inhibitors; 0 / Drugs, Investigational; 0 / Intercellular Signaling Peptides and Proteins; 0 / Neoplasm Proteins; 0 / Tumor Suppressor Protein p53
  • [Number-of-references] 105
  •  go-up   go-down


29. Saint F, Le Frere Belda MA, Quintela R, Hoznek A, Patard JJ, Bellot J, Popov Z, Zafrani ES, Abbou CC, Chopin DK, de Medina SG: Pretreatment p53 nuclear overexpression as a prognostic marker in superficial bladder cancer treated with Bacillus Calmette-Guérin (BCG). Eur Urol; 2004 Apr;45(4):475-82
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pretreatment p53 nuclear overexpression as a prognostic marker in superficial bladder cancer treated with Bacillus Calmette-Guérin (BCG).
  • INTRODUCTION: Altered p53 gene product correlates with the stage and grade of bladder tumor, but its value as a predictor of BCG response has been disappointing.
  • In order to revisit the prognostic value of pretreatment p53 nuclear overexpression for the BCG response, we studied a large cohort of consecutive patients with superficial bladder cancer treated with BCG.
  • METHODS: From 1988 to 2001, 102 patients with a history of multifocal, recurrent, and/or high-risk papillary transitional cell carcinoma or carcinoma in situ, were treated for the first time with BCG. p53 immunostaining was performed on paraffin-embedded tissues using monoclonal antibody DO7 and an automated immunostainer.
  • Times to recurrence, progression and cancer death were shorter among patients with p53 overexpression (p = 0.03; p < 0.0001; p = 0.0003).
  • CONCLUSION: Pretreatment p53 nuclear overexpression in superficial bladder tumors is associated with a high risk of disease recurrence, progression and cancer death after BCG therapy.
  • Applying antibody DO7 with an automated immunostainer and stringent fixative conditions, p53 nuclear immunostaining yields clinically relevant information and may be a useful tool for selecting patients with superficial bladder cancer who might be resistant to BCG.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. BCG Vaccine / therapeutic use. Carcinoma, Transitional Cell / drug therapy. Carcinoma, Transitional Cell / genetics. Tumor Suppressor Protein p53 / biosynthesis. Urinary Bladder Neoplasms / drug therapy. Urinary Bladder Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Nucleus. Disease Progression. Disease-Free Survival. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15041112.001).
  • [ISSN] 0302-2838
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / BCG Vaccine; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


30. Josephson DY, Pasin E, Stein JP: Superficial bladder cancer: part 1. Update on etiology, classification and natural history. Expert Rev Anticancer Ther; 2006 Dec;6(12):1723-34
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Superficial bladder cancer: part 1. Update on etiology, classification and natural history.
  • Superficial 'nonmuscle-invasive' bladder tumors represent a heterogeneous group of cancers, which include those that are papillary in nature and limited to the mucosa (Ta), high grade, flat and confined to the epithelium (Tis) and those that invade the submucosa or lamina propria (T1).
  • The natural history of these bladder cancers is that of disease recurrence and progression to higher grade and stage.
  • Furthermore, recurrence and progression rates of superficial bladder cancer vary according to several tumor characteristics.
  • The goal in the treatment of superficial bladder cancer is twofold: reducing tumor recurrence and the subsequent need for additional therapies, such as cystoscopy, transurethral resections, intravesical therapy and the morbidity associated with these treatments; and preventing tumor progression and the subsequent need for more aggressive therapy, such as radical cystectomy.
  • The administration of intravesical chemotherapy and immunotherapy has become an important component in accomplishing these goals.
  • This update is the first part of two articles reviewing important contemporary concepts in the etiology, classification and natural history of superficial bladder cancer, while part II of the series will review and highlight important aspects in management of superficial bladder cancer.
  • [MeSH-major] Urinary Bladder Neoplasms
  • [MeSH-minor] Carcinogens, Environmental / adverse effects. Carcinoma in Situ / diagnosis. Carcinoma in Situ / pathology. Carcinoma, Transitional Cell / classification. Carcinoma, Transitional Cell / diagnosis. Carcinoma, Transitional Cell / etiology. Carcinoma, Transitional Cell / genetics. Carcinoma, Transitional Cell / pathology. Carcinoma, Transitional Cell / therapy. Chromosome Aberrations. Diagnosis, Differential. Disease Progression. Hematuria / etiology. Humans. Mucous Membrane / pathology. Neoplasm Invasiveness. Neoplasm Staging. Occupational Diseases / chemically induced. Papilloma / diagnosis. Papilloma / pathology. Risk Factors. Smoking / adverse effects. Urinary Tract Infections / diagnosis

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17181486.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carcinogens, Environmental
  • [Number-of-references] 124
  •  go-up   go-down


31. Böhle A, Bock PR: Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology; 2004 Apr;63(4):682-6; discussion 686-7
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression.
  • OBJECTIVES: To compare the therapeutic efficacy of intravesical bacille Calmette-Guérin (BCG) with mitomycin C (MMC) on progression of Stage Ta and T1 bladder carcinoma.
  • METHODS: Combined published and unpublished data from comparative studies on BCG versus MMC in superficial bladder carcinoma were analyzed, considering possible confounding factors.
  • Within the overall median follow-up of 26 months, 7.67% of the patients in the BCG group and 9.44% of the patients in the MMC group developed tumor progression.
  • In the four studies without BCG maintenance, the combined result indicated no statistically significant difference between the two treatments (OR = 1.16; 95% CI 0.65 to 2.07; P = 0.612).
  • Potential confounders, such as tumor risk status, duration of follow-up, BCG strain, BCG and MMC treatment regimen, and year of publication did not significantly influence these results.
  • CONCLUSIONS: The results demonstrated statistically significant superiority for BCG compared with MMC for the prevention of tumor progression only if BCG maintenance therapy was provided.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. Antibiotics, Antineoplastic / therapeutic use. BCG Vaccine / therapeutic use. Mitomycin / therapeutic use. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Administration, Intravesical. Carcinoma, Papillary / drug therapy. Carcinoma, Papillary / pathology. Carcinoma, Papillary / prevention & control. Carcinoma, Transitional Cell / drug therapy. Carcinoma, Transitional Cell / pathology. Carcinoma, Transitional Cell / prevention & control. Disease Progression. Drug Administration Schedule. Follow-Up Studies. Humans. Neoplasm Staging. Randomized Controlled Trials as Topic. Treatment Outcome

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Urol. 2005 Mar;173(3):730-1 [15711255.001]
  • (PMID = 15072879.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Antibiotics, Antineoplastic; 0 / BCG Vaccine; 50SG953SK6 / Mitomycin
  •  go-up   go-down


32. Sylvester RJ, van der MEIJDEN AP, Lamm DL: Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol; 2002 Nov;168(5):1964-70
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials.
  • PURPOSE: We determine if intravesical bacillus Calmette-Guerin (BCG) reduces the risk of progression after transurethral resection to stage T2 disease or higher in patients with superficial (stage Ta, T1 or carcinoma in situ) bladder cancer.
  • MATERIALS AND METHODS: A meta-analysis was performed of the published results of randomized clinical trials comparing transurethral resection plus intravesical BCG to either resection alone or resection plus another treatment other than BCG.
  • The percent of patients with progression was low (6.4% of 2,880 patients with papillary tumors and 13.9% of 403 patients with carcinoma in situ, reflecting the short followup and relatively low risk patients entered in many of the trials.
  • The size of the treatment effect was similar in patients with papillary tumors and in those with carcinoma in situ.
  • There was no statistically significant difference in treatment effect for either overall survival or death due to bladder cancer.
  • CONCLUSIONS: Intravesical BCG significantly reduces the risk of progression after transurethral resection in patients with superficial bladder cancer who receive maintenance treatment.
  • Thus, it is the agent of choice for patients with intermediate and high risk papillary tumors and those with carcinoma in situ.
  • [MeSH-major] BCG Vaccine / administration & dosage. Carcinoma in Situ / drug therapy. Carcinoma, Transitional Cell / drug therapy. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Administration, Intravesical. Disease Progression. Humans. Neoplasm Staging. Randomized Controlled Trials as Topic. Survival Rate

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12394686.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 2U10 CA11488-31; United States / NCI NIH HHS / CA / 5U10 CA11488-32
  • [Publication-type] Comparative Study; Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCG Vaccine
  •  go-up   go-down


33. Ignatoff JM, Chen YH, Greenberg RE, Pow-Sang JM, Messing EM, Wilding G: Phase II study of intravesical therapy with AD32 in patients with papillary urothelial carcinoma or carcinoma in situ (CIS) refractory to prior therapy with bacillus Calmette-Guerin (E3897): a trial of the Eastern Cooperative Oncology Group. Urol Oncol; 2009 Sep-Oct;27(5):496-501
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of intravesical therapy with AD32 in patients with papillary urothelial carcinoma or carcinoma in situ (CIS) refractory to prior therapy with bacillus Calmette-Guerin (E3897): a trial of the Eastern Cooperative Oncology Group.
  • OBJECTIVE: To assess the safety and effectiveness of AD32, a doxorubicin analogue with little systemic exposure when administered intravesically, in patients with recurrent or refractory superficial urothelial carcinoma (formerly called transitional cell carcinoma [TCC]), or carcinoma in situ (CIS), who have failed prior BCG-based immunotherapy.
  • Treatment-related and GU-specific toxicities were also examined.
  • RESULTS: The study was halted due to unavailability of study drug after accrual of 48 of a planned 64 patients; 42 were included in the analysis.
  • Of 21 TCC patients, 18 (85.7%) experienced disease recurrence (median time to recurrence, 5.3 months).
  • Of the 5 CIS patients with complete response (CR), 3 (60%) experienced disease recurrence; (median time to recurrence, 37.3 months).
  • Infection was the most common treatment-related toxicity; no grade 4 or higher toxicity was observed.
  • CONCLUSIONS: AD32 is safe and active for treatment of recurrent or refractory superficial bladder carcinoma.
  • The agent awaits more complete characterization when drug production problems can be solved.

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urology. 2000 Aug 1;56(2):232-5 [10925084.001]
  • [Cites] Eur Urol. 2000;37 Suppl 1:33-6 [10575271.001]
  • [Cites] J Urol. 2001 May;165(5):1765-8 [11342972.001]
  • [Cites] Curr Probl Cancer. 2001 Jul-Aug;25(4):219-78 [11514784.001]
  • [Cites] Curr Treat Options Oncol. 2002 Oct;3(5):403-11 [12194805.001]
  • [Cites] Minerva Urol Nefrol. 2004 Mar;56(1):65-72 [15195031.001]
  • [Cites] Urology. 2004 Sep;64(3):409-21 [15351555.001]
  • [Cites] Cancer Res. 1975 May;35(5):1365-8 [1054622.001]
  • [Cites] Cancer Treat Rep. 1979 May;63(5):919-23 [455334.001]
  • [Cites] J Urol. 1991 Jan;145(1):40-3; discussion 43-4 [1984096.001]
  • [Cites] J Urol. 1985 Jul;134(1):40-7 [3892050.001]
  • [Cites] Recent Results Cancer Res. 1981;76:7-15 [7232854.001]
  • [Cites] J Urol. 1992 Mar;147(3):601-5 [1538437.001]
  • [Cites] J Urol. 1992 Apr;147(4):1020-3 [1552578.001]
  • [Cites] J Urol. 1994 Aug;152(2 Pt 1):367-73 [8015073.001]
  • [Cites] J Urol. 1995 May;153(5):1444-50 [7714962.001]
  • [Cites] Urology. 1997 Mar;49(3):471-5 [9123721.001]
  • [Cites] Int J Urol. 2007 Feb;14(2):140-6 [17302571.001]
  • [Cites] J Urol. 2007 Apr;177(4):1283-6; discussion 1286 [17382713.001]
  • [Cites] Nat Clin Pract Urol. 2007 May;4(5):254-60 [17483810.001]
  • [Cites] Int Urol Nephrol. 2000;32(1):53-8 [11057773.001]
  • (PMID = 18639470.001).
  • [ISSN] 1873-2496
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA21076; United States / NCI NIH HHS / CA / U10 CA027525; United States / NCI NIH HHS / CA / U10 CA066636-15; United States / NCI NIH HHS / CA / U10 CA011083-33; United States / NCI NIH HHS / CA / CA66636; United States / NCI NIH HHS / CA / U10 CA021115; United States / NCI NIH HHS / CA / CA27525; United States / NCI NIH HHS / CA / U10 CA021076-32; United States / NCI NIH HHS / CA / U10 CA017145; United States / NCI NIH HHS / CA / U10 CA027525-30; United States / NCI NIH HHS / CA / U10 CA021076; United States / NCI NIH HHS / CA / CA11083; United States / NCI NIH HHS / CA / CA011083-33; United States / NCI NIH HHS / CA / U10 CA066636; None / None / / U10 CA027525-30; None / None / / U10 CA023318-32; United States / NCI NIH HHS / CA / U10 CA017145-33; United States / NCI NIH HHS / CA / CA17145; United States / NCI NIH HHS / CA / U10 CA021115-34; None / None / / U10 CA021115-34; United States / NCI NIH HHS / CA / U10 CA023318-32; None / None / / U10 CA017145-33; United States / NCI NIH HHS / CA / U10 CA023318; United States / NCI NIH HHS / CA / U10 CA011083; United States / NCI NIH HHS / CA / CA21115; United States / NCI NIH HHS / CA / CA23318; United States / NCI NIH HHS / CA / CA021076-32; None / None / / U10 CA066636-15
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / BCG Vaccine; 80168379AG / Doxorubicin
  • [Other-IDs] NLM/ NIHMS104680; NLM/ PMC2743955
  •  go-up   go-down


34. Ayari C, LaRue H, Hovington H, Decobert M, Harel F, Bergeron A, Têtu B, Lacombe L, Fradet Y: Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy. Eur Urol; 2009 Jun;55(6):1386-95
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy.
  • OBJECTIVE: To measure tumor infiltration by CD83(+) dendritic cells (DCs) and CD68(+) macrophages in non-muscle-invasive urothelial cancer (NMIUC) prior to bacillus Calmette-Guérin (BCG) immunotherapy and to evaluate their significance in the response to immunotherapy.
  • MEASUREMENTS: Immunohistochemical staining with anti-CD83 and anti-CD68 monoclonal antibodies on 53 and 46 NMIUC tumors, respectively, prior to BCG treatment.
  • A scoring index was calculated based on the average density of positive cells within the papillary axis, the stroma, lymphoid aggregates, and infiltration into tumors.
  • Multivariate Cox regression analysis showed that maintenance BCG (more than one maintenance cycle) was highly effective in patients with a low level of CD83(+) TIDCs at time of resection (hazard ratio [HR]: 0.035; p=0.002) but showed reduced efficacy in patients with a high level of CD83(+) TIDCs (HR: 0.87; p=0.810).
  • If confirmed in larger cohorts, the pretreatment level of infiltration by these cells may be useful to influence the choice of treatment strategy.
  • [MeSH-major] Antigens, CD / metabolism. Antigens, Differentiation, Myelomonocytic / metabolism. BCG Vaccine / therapeutic use. Biomarkers, Tumor / analysis. Carcinoma, Transitional Cell / drug therapy. Dendritic Cells / immunology. Macrophages / immunology. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Administration, Intravesical. Aged. Biopsy, Needle. Cohort Studies. Cystectomy / methods. Female. Humans. Immunohistochemistry. Immunotherapy / methods. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Predictive Value of Tests. Probability. Prognosis. Risk Assessment. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur Urol. 2009 Jun;55(6):1395-6 [19193488.001]
  • (PMID = 19193487.001).
  • [ISSN] 1873-7560
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / BCG Vaccine; 0 / Biomarkers, Tumor; 0 / CD68 antigen, human
  •  go-up   go-down


35. Takagi S, Gohji K, Iwamoto Y, Masuda H, Segawa N, Kiura H, Ueda H, Katsuoka Y: [Ureter cancer of complete double renal pelvis and ureter: a case report]. Hinyokika Kiyo; 2002 Dec;48(12):761-4
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intravenous pyelography, computerized tomography and magnetic resonance imaging revealed ureteral tumors of the complete left double renal pelvis and the ureter.
  • An endoscopic examination disclosed a papillary tumor from the left ureteral orifice of the lower pole of the kidney.
  • A transurethral resection of the tumor was done, and the pathological features revealed transitional cell carcinoma (PTa, grade 2).
  • A left nephroureterectomy and a partial cystectomy were also carried out; macroscopic examinations showed a non-papillary tumor on the middle portion of the left ureter originating from the upper pole of the kidney.
  • Microscopic examinations revealed transitional cell carcinoma (PT3, grade 3, PL1, PV1).
  • Adjuvant chemotherapy (M-VAC) was administered but discontinued because of severe side effects.
  • Dispite recurrence with retro-peritoneal lymph node metastasis, the patient is alive and again undergoing M-VAC chemotherapy 22 months after the initial surgery.
  • However, the evaluation of the chemotherapy was "no change".
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Kidney Neoplasms / surgery. Kidney Pelvis / abnormalities. Neoplasms, Multiple Primary. Ureter / abnormalities. Ureteral Neoplasms / surgery
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Humans. Lymphatic Metastasis. Male. Neoplasm Recurrence, Local. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / surgery. Urologic Surgical Procedures

  • Genetic Alliance. consumer health - Kidney cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12613013.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 16
  •  go-up   go-down


36. Brandt WD, Matsui W, Rosenberg JE, He X, Ling S, Schaeffer EM, Berman DM: Urothelial carcinoma: stem cells on the edge. Cancer Metastasis Rev; 2009 Dec;28(3-4):291-304
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urothelial carcinoma: stem cells on the edge.
  • This variability likely stems from epigenetic and genetic influences, either stochastic or hardwired by cell type-specific lineage programs.
  • That differentiation underlies tumor cell heterogeneity was elegantly demonstrated in hematopoietic tumors, in which rare primitive cells (cancer stem cells (CSCs)) resembling normal hematopoietic stem cells are ultimately responsible for tumor growth and viability.
  • Because of the compelling clinical implications CSCs pose--across the entire spectrum of cancers--investigators applied the CSC model to cancers arising in tissues with crudely understood differentiation programs.
  • The recent identification of urothelial differentiation programs in urothelial carcinomas (UroCas) supports the idea that solid epithelial cancers (carcinomas) develop and differentiate analogously to normal epithelia and provides new insights about the spatial localization and molecular makeup of carcinoma CSCs.
  • Importantly, CSCs from invasive UroCas (UroCSCs) appear well situated to exchange important signals with adjacent stroma, to escape immune surveillance, and to survive cytotoxic therapy.
  • These signals have potential roles in treatment resistance and many participate in druggable cellular pathways.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Res. 2008 May;18(5):523-7 [18392048.001]
  • [Cites] Br J Urol. 1994 May;73(5):516-21 [8012773.001]
  • [Cites] Nature. 2006 May 25;441(7092):518-22 [16633340.001]
  • [Cites] Nature. 2006 May 25;441(7092):418-9 [16724049.001]
  • [Cites] Hepatology. 2006 Jul;44(1):240-51 [16799977.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11154-9 [16849428.001]
  • [Cites] Nature. 2006 Aug 17;442(7104):818-22 [16862118.001]
  • [Cites] Cancer Res. 2006 Oct 1;66(19):9339-44 [16990346.001]
  • [Cites] Nat Med. 2006 Oct;12(10):1167-74 [16998484.001]
  • [Cites] Acta Haematol. 2007;117(1):8-15 [17095854.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):111-5 [17122771.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):106-10 [17122772.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):973-8 [17210912.001]
  • [Cites] N Engl J Med. 2007 Jan 18;356(3):217-26 [17229949.001]
  • [Cites] J Clin Invest. 2007 Feb;117(2):314-25 [17256055.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):259-73 [17349583.001]
  • [Cites] Endocrinology. 2007 Apr;148(4):1797-803 [17234707.001]
  • [Cites] J Clin Invest. 2007 May;117(5):1175-83 [17476347.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10158-63 [17548814.001]
  • [Cites] Cell. 2007 Jun 15;129(6):1097-110 [17574023.001]
  • [Cites] Science. 2007 Jul 20;317(5836):337 [17641192.001]
  • [Cites] Nature. 2007 Oct 4;449(7162):557-63 [17914389.001]
  • [Cites] Cell Cycle. 2007 Oct 1;6(19):2332-8 [17786053.001]
  • [Cites] Annu Rev Pathol. 2006;1:119-50 [18039110.001]
  • [Cites] Science. 2007 Dec 14;318(5857):1722; author reply 1722 [18079385.001]
  • [Cites] Cancer Res. 2008 Jan 1;68(1):190-7 [18172311.001]
  • [Cites] Cell Death Differ. 2008 Mar;15(3):504-14 [18049477.001]
  • [Cites] Cell. 2008 Feb 22;132(4):598-611 [18295578.001]
  • [Cites] Cell Stem Cell. 2007 Oct 11;1(4):389-402 [18371377.001]
  • [Cites] Am J Physiol Renal Physiol. 2008 Jun;294(6):F1415-21 [18367656.001]
  • [Cites] PLoS One. 2008;3(6):e2428 [18560594.001]
  • [Cites] Cancer Invest. 2008 Aug;26(7):725-33 [18608209.001]
  • [Cites] Nat Rev Cancer. 2008 Oct;8(10):755-68 [18784658.001]
  • [Cites] Blood. 2008 Nov 1;112(9):3543-53 [18948588.001]
  • [Cites] Nature. 2008 Dec 4;456(7222):593-8 [19052619.001]
  • [Cites] Int J Cancer. 2009 Jan 1;124(1):103-8 [18844223.001]
  • [Cites] Curr Opin Oncol. 2009 Jan;21(1):41-6 [19125017.001]
  • [Cites] Cell Cycle. 2009 Jan 1;8(1):158-66 [19158483.001]
  • [Cites] Mol Cancer Ther. 2009 Feb;8(2):458-68 [19174556.001]
  • [Cites] Genes Dev. 2009 Mar 15;23(6):675-80 [19261747.001]
  • [Cites] Nature. 2009 Apr 9;458(7239):780-3 [19194462.001]
  • [Cites] Cancer Res. 2009 Apr 15;69(8):3364-73 [19351829.001]
  • [Cites] J Int Med Res. 2009 May-Jun;37(3):621-30 [19589244.001]
  • [Cites] Cell. 2009 Jul 23;138(2):226-8 [19632173.001]
  • [Cites] Cell. 2009 Jul 23;138(2):286-99 [19632179.001]
  • [Cites] Stem Cells. 2009 Jul;27(7):1487-95 [19544456.001]
  • [Cites] Cell. 2009 Aug 21;138(4):645-59 [19682730.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Aug 18;106(33):14016-21 [19666525.001]
  • [Cites] Ann N Y Acad Sci. 2009 Aug;1171:59-76 [19723038.001]
  • [Cites] Int J Cancer. 2009 Nov 1;125(9):2095-103 [19637316.001]
  • [Cites] Ann N Y Acad Sci. 2009 Sep;1176:144-9 [19796242.001]
  • [Cites] Stem Cells Dev. 2009 Dec;18(10):1515-22 [19260804.001]
  • [Cites] Oncol Rep. 2000 Jan-Feb;7(1):13-6 [10601583.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Blood. 2000 Mar 1;95(5):1758-66 [10688835.001]
  • [Cites] Am J Physiol Renal Physiol. 2000 Jun;278(6):F867-74 [10836974.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3068-77 [11001674.001]
  • [Cites] Ann Oncol. 2000 Jul;11(7):851-6 [10997813.001]
  • [Cites] Am J Pathol. 2001 Jun;158(6):1955-9 [11395371.001]
  • [Cites] Nat Med. 2001 Sep;7(9):1028-34 [11533706.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):105-11 [11689955.001]
  • [Cites] Blood. 2002 Jan 1;99(1):319-25 [11756187.001]
  • [Cites] Int J Oncol. 2002 May;20(5):905-11 [11956582.001]
  • [Cites] Histopathology. 2002 May;40(5):403-39 [12010363.001]
  • [Cites] J Urol. 2002 Aug;168(2):709-17 [12131357.001]
  • [Cites] J Pathol. 2002 Oct;198(2):245-51 [12237885.001]
  • [Cites] Int J Cancer. 2003 Jan 20;103(3):328-34 [12471615.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):90-6 [12469123.001]
  • [Cites] Adv Drug Deliv Rev. 2003 Jan 21;55(1):3-29 [12535572.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] Am J Pathol. 2003 Aug;163(2):493-504 [12875970.001]
  • [Cites] N Engl J Med. 2003 Aug 28;349(9):859-66 [12944571.001]
  • [Cites] J Pathol. 2003 Oct;201(2):204-12 [14517837.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 20;101(3):781-6 [14711994.001]
  • [Cites] Blood. 2004 Mar 15;103(6):2332-6 [14630803.001]
  • [Cites] Lab Invest. 2004 Apr;84(4):465-78 [14968126.001]
  • [Cites] J Immunol. 2004 May 1;172(9):5467-77 [15100288.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):4040-8 [15173019.001]
  • [Cites] Genes Dev. 2004 Aug 1;18(15):1875-85 [15289459.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 28;101(39):14228-33 [15381773.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7183-90 [15492230.001]
  • [Cites] Am J Obstet Gynecol. 1969 Mar 15;103(6):810-22 [5765964.001]
  • [Cites] J Anat. 1972 Sep;112(Pt 3):433-55 [4636798.001]
  • [Cites] Cancer Res. 1976 Jul;36(7 PT 1):2326-9 [1277137.001]
  • [Cites] Science. 1976 Oct 1;194(4260):23-8 [959840.001]
  • [Cites] Virchows Arch B Cell Pathol. 1976 Oct 1;21(4):279-98 [824809.001]
  • [Cites] Science. 1983 Jun 10;220(4602):1175-7 [6304875.001]
  • [Cites] Blood. 1990 May 15;75(10):1947-50 [2337669.001]
  • [Cites] J Biol Chem. 1990 Nov 5;265(31):19170-9 [2229070.001]
  • [Cites] Cancer Treat Res. 1991;53:335-64 [1672086.001]
  • [Cites] Blood. 1993 Jun 1;81(11):2898-902 [8499629.001]
  • [Cites] Nature. 1994 Feb 17;367(6464):645-8 [7509044.001]
  • [Cites] Acta Anat (Basel). 1996;155(3):163-71 [8870784.001]
  • [Cites] Cancer Res. 1997 Apr 1;57(7):1217-21 [9102201.001]
  • [Cites] Nat Med. 1997 Jul;3(7):730-7 [9212098.001]
  • [Cites] Br J Cancer. 1998;77(2):319-24 [9461004.001]
  • [Cites] Cancer Res. 1998 Mar 15;58(6):1090-4 [9515785.001]
  • [Cites] Clin Cancer Res. 1998 Apr;4(4):829-34 [9563875.001]
  • [Cites] Am J Obstet Gynecol. 1998 Apr;178(4):641-9 [9579425.001]
  • [Cites] Cancer Res. 1999 Jul 15;59(14):3512-7 [10416618.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):5002-11 [10519415.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8585-94 [15574765.001]
  • [Cites] Cancer Cell. 2005 Jan;7(1):17-23 [15652746.001]
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3790-8 [15897578.001]
  • [Cites] Clin Cancer Res. 2005 Jun 15;11(12):4415-29 [15958626.001]
  • [Cites] Nature. 2005 Jun 30;435(7046):1267-70 [15988530.001]
  • [Cites] Eur Urol. 2005 Aug;48(2):202-5; discussion 205-6 [15939524.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6207-19 [16024622.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23(21):4602-8 [16034041.001]
  • [Cites] Dev Cell. 2005 Aug;9(2):173-83 [16054025.001]
  • [Cites] Nat Rev Cancer. 2005 Sep;5(9):713-25 [16110317.001]
  • [Cites] Clin Cancer Res. 2005 Nov 1;11(21):7709-19 [16278391.001]
  • [Cites] Eur J Cancer. 2006 Jan;42(1):50-4 [16330205.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):383-91 [16428476.001]
  • [Cites] Oncogene. 2006 Mar 9;25(10):1554-9 [16261162.001]
  • [Cites] Oncogene. 2006 Mar 16;25(12):1696-708 [16449977.001]
  • [Cites] Stem Cells. 2006 Mar;24(3):506-13 [16239320.001]
  • [Cites] Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2109-16 [16609023.001]
  • [Cites] Cochrane Database Syst Rev. 2006;(2):CD006018 [16625650.001]
  • [Cites] Nature. 2006 May 25;441(7092):475-82 [16598206.001]
  • (PMID = 20012172.001).
  • [ISSN] 1573-7233
  • [Journal-full-title] Cancer metastasis reviews
  • [ISO-abbreviation] Cancer Metastasis Rev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA067751-13; United States / NIDDK NIH HHS / DK / R01DK072000; United States / NCI NIH HHS / CA / T32 CA067751-13; United States / NIDDK NIH HHS / DK / R01 DK072000-04; United States / NCI NIH HHS / CA / P01CA077664; United States / NIDDK NIH HHS / DK / R01 DK072000; United States / NCI NIH HHS / CA / CA077664-10; United States / NCI NIH HHS / CA / P01 CA077664-10; United States / NIDDK NIH HHS / DK / DK072000-04; United States / NCI NIH HHS / CA / P01 CA077664
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Wnt Proteins
  • [Number-of-references] 121
  • [Other-IDs] NLM/ NIHMS224847; NLM/ PMC2930269
  •  go-up   go-down






Advertisement